Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1

Arsenic trioxide plus PX-478 achieves effective treatment in pancreatic ductal adenocarcinoma

(2016) Mingxiao Lang et al.   CANCER LETTERS

Melatonin enhances arsenic trioxide-induced cell death via sustained upregulation of Redd1 expression in breast cancer cells

(2016) Sun-Mi Yun et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Metformin enhances radiation response of ECa109 cells through activation of ATM and AMPK

(2015) Tingting Feng et al.   BIOMEDICINE & PHARMACOTHERAPY

Arsenic trioxide induces programmed cell death through stimulation of ER stress and inhibition of the ubiquitin–proteasome system in human sarcoma cells

(2015) Hui-Wen Chiu et al.   CANCER LETTERS

Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes

(2015) Hengyi Chen et al.   CANCER LETTERS

Metformin does not improve survival of cholangiocarcinoma patients with diabetes

(2015) Zhen Yang et al.   HEPATOLOGY

The combination of arsenic and cryptotanshinone induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in breast cancer cells

(2015) Yan Fang Zhang et al.   Metallomics

A novel role for atypical MAPK kinase ERK3 in regulating breast cancer cell morphology and migration

(2015) Rania Al-Mahdi et al.   Cell Adhesion & Migration

Metformin inhibits tumor growth by regulating multiple miRNAs in human cholangiocarcinoma

(2015) Xingming Jiang et al.   Oncotarget

Mutations and Deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascades

(2015) James Andrew McCubrey et al.   Oncotarget

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance

(2015) James Andrew McCubrey et al.   Oncotarget

Cholangiocarcinoma

(2014) Nataliya Razumilava et al.   LANCET

Metformin sensitizes hepatocellular carcinoma to arsenic trioxide-induced apoptosis by downregulating Bcl2 expression

(2014) Xuejun Yang et al.   TUMOR BIOLOGY

Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: Implications for the treatment of human liver cancer

(2013) Chunmei Wang et al.   CELL CYCLE

Anticancer effect of arsenic trioxide on cholangiocarcinoma: in vitro experiments and in vivo xenograft mouse model

(2013) Eun-Young Kim et al.   CLINICAL AND EXPERIMENTAL MEDICINE

Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes

(2013) Daniela Sia et al.   GASTROENTEROLOGY

Activation of mammalian target of rapamycin complex 1 (mTORC1) and Raf/Pyk2 by growth factor-mediated Eph receptor 2 (EphA2) is required for cholangiocarcinoma growth and metastasis

(2013) Xiang-Dan Cui et al.   HEPATOLOGY

Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines

(2012) Fatima Rangwala et al.   BMC CANCER

Risk factors for intrahepatic cholangiocarcinoma: Association between metformin use and reduced cancer risk

(2012) Roongruedee Chaiteerakij et al.   HEPATOLOGY

The Tyrosine Kinase c-Met Contributes to the Pro-tumorigenic Function of the p38 Kinase in Human Bile Duct Cholangiocarcinoma Cells

(2012) Rongyang Dai et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion

(2012) Weiwen Long et al.   JOURNAL OF CLINICAL INVESTIGATION

Risk factors for cholangiocarcinoma

(2011) Gia L. Tyson et al.   HEPATOLOGY

Inactivation of Rheb by PRAK-mediated phosphorylation is essential for energy-depletion-induced suppression of mTORC1

(2011) Min Zheng et al.   NATURE CELL BIOLOGY

Mitogen-activated protein kinase p38 and MK2, MK3 and MK5: Ménage à trois or ménage à quatre?

(2010) Alexey Shiryaev et al.   CELLULAR SIGNALLING

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer

(2008) Magnus Rizell et al.   International Journal of Clinical Oncology